Transview Life: has not applied for self-testing COVID-19 testing products

Beijing News (Reporter Zhang Zhaohui) On March 16, Transview Life insurance said on its interactive platform that it has not applied to the State Food and Drug Administration for self-testing COVID-19 test products in response to investors’ questions about whether it has COVID-19 antigen test products.Previously, novel Coronavirus antigen test kits (chemiluminescence immunoassay) have obtained the CE qualification of the European Union, which requires qualified professional medical institutions or personnel to carry out the test operation.The Novel Coronavirus 2019 Nucleic acid Test kit (Card-type fluorescence PCR) has been applied for registration with the SFDA.Beijing News reporters found that on January 10, 2022, Diking Life Received the Notification of Acceptance of novel Coronavirus 2019 nucleic acid test kit (card-type fluorescence PCR) issued by the STATE Food and Drug Administration.The kit is used for in vitro qualitative detection of novel Coronavirus (2019-NCOV) ORF1ab and N genes in throat swabs and sputum samples of suspected pneumonia cases, suspected clusters of suspected coronavirus cases, and other persons requiring diagnosis or differential diagnosis of Novel Coronavirus infection.Treview Life was founded in 2003, located in Shanghai Zhangjiang High-tech Park, known as “China’s pharmaceutical Valley”, and listed on April 21, 2017.Diking Life has launched a series of innovative products in tumor detection, cervical cancer screening, DNA methylation detection, male infertility, eugenics and other fields.Proofreading Lu Qian

Leave a Reply

Your email address will not be published.